Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies worldwide, associated with poor prognosis even when diagnosed at an early clinical stage (CS). Despite advances in surgery, radiotherapy, and chemotherapy, the 5-year overall survival rate is only 7.0-8.5% [1]. FOLFIRINOX (5-fluorouracil, irinotecan, and oxaliplatin) and nab-paclitaxel plus gemcitabine are first-line treatment options in the metastatic setting, with a median overall survival of less than 1 year [2,3].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Taiane F. Rebelatto, Maicon Falavigna, Marta Pozzari, Francesca Spada, Chiara A. Cella, Alice Laffi, Stefania Pellicori, Nicola Fazio Tags: Systematic or Meta-analysis Studies Source Type: research
More News: Adenocarcinoma | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Eloxatin | Genetics | Pancreas | Pancreatic Cancer | Study